Profiling of Hydroxyurea-treated β-thalassemia Serum Proteome through Nano-LC-ESI-MS/MS in combination with MicroSol-Isoelectric Focusing.
Advancements in proteomic tools offer a comprehensive solution to study the complexity of diseases, at molecular level. This study focusses on the clinical proteomic profiling of pre- and post- hydroxyurea (HU)-treated β-thalassemia patients parallel with healthy individuals to better understand the role of hydroxyurea in the treatment of β-thalassemia. The strategy encompasses sequential high-resolution protein fractionation using MicroSol-isoelectric focusing (ZOOM- IEF) followed by one-dimensional SDS-PAGE before subjecting to nano-RP-LC-MS/MS analysis of tryptic peptides. Protein identification was performed through Mascot search using NCBInr and SwissProt databases. Several differential proteins were observed in pool serum samples of each of the three study groups. Approximately, 1250 proteins exclusive to each group were identified and after removing the redundant and low sequence coverage proteins, the number was reduced to 576 (201 in healthy, 187 in HU-untreated, 188 in HU-treated group). Uniquely identified proteins in HU-treated group regulate the focal adhesion, ECM-receptor interaction, PI3K-Akt signaling, Rap1 signaling, cAMP signaling, platelet activation, and Ca2+ signaling pathways in HU-treated group. The proteomic profile presented here will add to the current state of understanding of molecular mechanisms involved in hydroxyurea treatment of β-thalassemia.